Henlius
Innovative Biopharmaceutical Company
Abbott
Diagnostic and pharmaceutical product manufacturers
Fosun Pharmaceutical
Healthcare Industry Group
On January 13, 2025, Fosun Pharmaceutical's subsidiary Shanghai Henlius Biotech, Inc. (2696.HK) announced that it had signed a licensing agreement with Abbott. The agreement grants Abbott exclusive or semi-exclusive rights to develop and commercialize four biosimilars and one innovative biologic independently developed by the company in 69 emerging market countries and regions. The agreement covers Asia, Latin America and the Caribbean, as well as the Middle East and North Africa. This licensing agreement further deepens the existing collaboration between the two parties in the field of oncology biosimilars.
Under the new agreement, the first batch of molecular candidates is expected to be launched by 2027, with the remaining products pending completion of clinical development and registration. Abbott will be responsible for the marketing authorization of the collaborative products within the collaboration region and leverage the extensive influence and industry leadership of its existing business to promote the market adoption of the collaborative products. As an international biopharmaceutical company focusing on oncology, autoimmune diseases, and ophthalmic diseases, Shanghai Henlius Biotech, Inc. will manufacture these drugs at its GMP-certified production base located in Shanghai.
This expanded collaboration between the two parties is dedicated to making high-quality, affordable advanced biologics accessible to patients worldwide, further fulfilling their commitment to provide more advanced treatment options in emerging markets.
Senior Vice President and Chief Business Development Officer of Shanghai Henlius Biotech, Inc.
Ms. Cao Ping
Shanghai Henlius Biotech, Inc. is delighted to further deepen its cooperation with Abbott. Abbott, with its trusted high-quality mature medicines, continuous technological innovation capabilities, and comprehensive local distribution network, has achieved steady growth in emerging markets and has become a leading enterprise in the healthcare sector of these markets. This renewed collaboration between the two parties strongly demonstrates their shared vision of promoting global health accessibility. We firmly believe that by integrating the resources and expertise of both sides, we will provide efficient health solutions to emerging markets and further enhance the overall level of local oncology treatment.
Shanghai, China, January 13, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) ，a subsidiary of Fosun pharma announced it has entered into product license and supply agreement with Abbott, granting it exclusive or semi-exclusive licenses for the commercialization of four self-developed biosimilars and one innovative biologic in 69 emerging markets in Asia, Latin America and the Caribbean, as well as Middle East and Africa. This agreement builds on an existing collaboration between the two companies for the commercialization of oncology biosimilars.
Under this new agreement, the first molecules are anticipated to be launched in 2027, with some still subject to the completion of clinical development and registration. Abbott will secure the molecule registration in these regions and will launch the products by leveraging its broad presence and leadership position through its existing business. Henlius, a global biologics company focusing on oncology, autoimmune and ophthalmic diseases, will manufacture the medicines in its GMP-approved facility in Shanghai.
The expanded collaboration aims to enhance global access for patients to high-quality, affordable advanced biologics, reinforcing the commitment of both parties to deliver more advanced treatment options in emerging markets.
Ping Cao, Senior Vice President and Chief Business Development Officer of Henlius, said, “Henlius is delighted to reaffirm our collaboration with Abbott, a healthcare leader in emerging markets, realizing consistent growth with its trusted, high-quality established products, continuous technological advancements, and comprehensive local distribution networks. This expanded agreement is a testament of our common focus on expanding access to health, globally. We are confident that by pooling our joint efforts and expertise, we can deliver effective health solutions to emerging markets and improve standards of care for oncology.”
